Market Updates

China Indexes Halted 2-Day Sell-Off as Bargain Hunters Stepped In

Li Chen
06 Nov, 2025
Hong Kong

    Stocks in China and Hong Kong rebounded, tracking gains in overnight trading in New York. 

    The Hang Seng Index increased 1.7%, and the mainland-focused CSI 300 index advanced 1.3% as bargain hunters returned.

    Technology stocks led gainers in Hong Kong, and financials dominated trading in Shanghai ahead of quarterly results and international trade data. 

    Investors reviewed the U.S. Supreme Court's oral arguments in tariff cases, and justices appear skeptical about the U.S. president's authority to impose sweeping tariffs without approvals from the U.S. Congress.

    The Trump administration is likely to seek other ways to impose import taxes, but those taxes will be limited in scope and targeted to certain industries. 

    The tariffs case filed by seven small businesses and 12 U.S. states led by Oregon was consolidated by the U.S. Supreme Court, and the court is set to announce its decision before the end of its term in July 2026.

    The Trump administration's tariffs faced significant opposition from two lower courts, and they ruled them illegal.  

     

    China Indexes and Stocks 

    The Hang Seng Index advanced 1.7% to 26,362.15, and the mainland-focused CSI 300 index increased 1.3% to 4,686.45. 

    Four mainland China-based companies listed their stocks on the Hong Kong Stock Exchange. 

    Ningbo Joyson Electronic decreased 3% to HK $21.35, and the automotive supplier priced its initial public offering at HK $22.0 a share and raised net proceeds of HK $3.2 billion. 

    Pony.ai Inc. dropped 12% to HK $122.60, and the autonomous driving company priced its offering at HK $139.0 a share and raised net proceeds of HK $6.5 billion. 

    WeRide Inc. dropped 14% to HK $23.40, and the autonomous driving company priced its initial offering at HK $27 a share and raised net proceeds of HK $2.2 billion. 

    Vigonvita Life Sciences soared more than 145% to HK $85.10, and the neuropsychiatry- and reproductive health-focused company priced its initial public offering at HK $33.37 a share and raised net proceeds of HK $527.4 million. 

     

Annual Returns

Company Ticker 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Earnings

Company Ticker 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008